sniff results
“GLP-1”
145 total hits · 0 drugs · 0 companies · 0 diseases · 13 catalysts · 132 news
Drugs(0)
expand →
no drug names matched
🐶 Companies(0)
expand →
no companies matched
Catalysts(13)
expand →
Sep 1, 2028
phase readout
Trial primary completion: Effects of Dietary Supplements on Muscle Mass and Function While Using GLP-1 Medication
→
Jun 1, 2028
phase readout
Trial primary completion: Effects of GLP-1 RAs on Human Lactation Outcomes
→
Nov 1, 2026
phase readout
Trial primary completion: Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy
→
Apr 17, 2026
grant
UNIVERSITY OF MICHIGAN AT ANN ARBOR — Remote Loading of Melanocortin and GLP-1 Peptides in Polymers for Treatment o...
→
Mar 23, 2026
grant
UNIVERSITY OF FLORIDA — Navigating the Uncertainties of Thyroid Cancer Risk in GLP-1RA Users
University of Florida
→
Mar 15, 2026
grant
MAYO CLINIC ROCHESTER — Real world impact of glucagon-like peptide receptor agonist (GLP-1 RA) use on...
Mayo Clinic
→
Feb 15, 2026
grant
UNIVERSITY OF CINCINNATI — GLP-1 Agonists for Preventing Alzheimer's Disease in Mild Cognitive Impairment
Metallomix Inc
→
Sep 18, 2025
grant
EMORY UNIVERSITY — From Evidence to Policy: Tailoring GLP-1RA Coverage for Optimal Health Outcomes
Emory University
→
News(132)
expand →
- Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting gameLilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.biopharma dive · 9h ago
- Lilly’s guidance has jumped by $10B as GLP-1 sales keep blowing past expectationsWith the commercial business performing so well, Eli Lilly is eyeing earlier business development bets to build out a longer-term pipeline.biospace · 1d ago
- Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellersEli Lilly’s shares rose 4% in early morning trading after reporting revenue of $24.4 billion, well past consensus estimates.biospace · 1d ago
- Ascletis’ challenger to Lilly’s Foundayo hits goals in phase 2 diabetes trial